Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Finished Goods (2019 - 2022)

Marimed (MRMD) has disclosed Finished Goods for 4 consecutive years, with $5.3 million as the latest value for Q1 2022.

  • On a quarterly basis, Finished Goods rose 70.88% to $5.3 million in Q1 2022 year-over-year; TTM through Mar 2022 was $5.3 million, a 70.88% increase, with the full-year FY2021 number at $3.8 million, up 35.17% from a year prior.
  • Finished Goods was $5.3 million for Q1 2022 at Marimed, up from $3.8 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $5.8 million in Q3 2021 to a low of $518166.0 in Q4 2019.
  • A 4-year average of $3.8 million and a median of $3.8 million in 2021 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 446.82% in 2020, then surged 35.17% in 2021.
  • Marimed's Finished Goods stood at $518166.0 in 2019, then skyrocketed by 446.82% to $2.8 million in 2020, then soared by 35.17% to $3.8 million in 2021, then soared by 37.47% to $5.3 million in 2022.
  • Per Business Quant, the three most recent readings for MRMD's Finished Goods are $5.3 million (Q1 2022), $3.8 million (Q4 2021), and $5.8 million (Q3 2021).